GlaxoSmithKline PLC (NYSE:GSK) – Jefferies Group reduced their FY2017 earnings per share estimates for GlaxoSmithKline PLC in a note issued to investors on Tuesday. Jefferies Group analyst J. Holford now expects that the pharmaceutical company will earn $2.91 per share for the year, down from their previous estimate of $2.98.

WARNING: “Brokers Issue Forecasts for GlaxoSmithKline PLC’s FY2017 Earnings (GSK)” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/02/brokers-issue-forecasts-for-glaxosmithkline-plcs-fy2017-earnings-gsk.html.

Other equities analysts also recently issued reports about the stock. Citigroup Inc. downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 5th. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 13th. Zacks Investment Research raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price target for the company in a research note on Tuesday, July 18th. BidaskClub downgraded shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Finally, TheStreet downgraded shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research note on Wednesday, July 26th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $44.33.

Several hedge funds and other institutional investors have recently made changes to their positions in GSK. Renaissance Technologies LLC increased its stake in shares of GlaxoSmithKline PLC by 112.1% during the second quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock valued at $402,655,000 after purchasing an additional 4,935,900 shares in the last quarter. FMR LLC increased its stake in shares of GlaxoSmithKline PLC by 5.9% during the second quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock valued at $1,079,047,000 after purchasing an additional 1,389,238 shares in the last quarter. Bank of America Corp DE increased its stake in shares of GlaxoSmithKline PLC by 15.8% during the first quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock valued at $288,780,000 after purchasing an additional 934,928 shares in the last quarter. Federated Investors Inc. PA increased its stake in shares of GlaxoSmithKline PLC by 22.7% during the second quarter. Federated Investors Inc. PA now owns 4,511,155 shares of the pharmaceutical company’s stock valued at $194,521,000 after purchasing an additional 833,501 shares in the last quarter. Finally, Marshall Wace North America L.P. increased its stake in shares of GlaxoSmithKline PLC by 148.0% during the second quarter. Marshall Wace North America L.P. now owns 1,119,491 shares of the pharmaceutical company’s stock valued at $48,138,000 after purchasing an additional 668,088 shares in the last quarter. 9.29% of the stock is owned by institutional investors and hedge funds.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 11th. Shareholders of record on Friday, November 10th will be paid a dividend of $0.5037 per share. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.53%. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is currently 162.30%.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Earnings History and Estimates for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.